Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes

Hara, Kimihiko

doi:10.1016/s1386-6346(02)00088-8

Cited by 100 publications

(76 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[2][3][4] We have confirmed that lactoferrin protects against the development of hepatitis caused by sensitization of Kupffer cells by lipopolysaccaride. 5) Lactoferrin also inhibits production of the inflammatory cytokines tumor necrosis factor (TNF)-interleukin (IL)-1 and IL-6 in monocytes.…”

mentioning

confidence: 54%

Hepatoprotective Effects of Whey Protein onD-Galactosamine-Induced Hepatitis and Liver Fibrosis in Rats

Kume¹,

Okazaki²,

Sasaki³

2006

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

mentioning

confidence: 54%

Hepatoprotective Effects of Whey Protein onD-Galactosamine-Induced Hepatitis and Liver Fibrosis in Rats

Kume¹,

Okazaki²,

Sasaki³

2006

Bioscience, Biotechnology, and Biochemistry

View full text Add to dashboard Cite

“…116 Recent studies have also shown anti-HBV effects of lactoferrin. 126,127 Benefits of exclusive breastfeeding in reducing HIV transmission has been suggested. Small changes in the rate of suckling or non-exclusive breastfeeding could be associated with milk stasis and breast engorgement.…”

Section: Chronic Hepatitis B Virus Infected Mother and Safety Of Breamentioning

confidence: 99%

Chronic Hepatitis B Virus Infection and Pregnancy

Kumar

Singh

Sinha

2012

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Planning of pregnancy and management of chronic hepatitis B virus during pregnancy includes recognition of maternal virological status, assessment of liver disease severity and minimization of risk for mother to infant transmission of infection. Decisions regarding the use of antivirals during pregnancy need to be individualized. Monitoring for infection and immunization in newborns is also important. For mothers on antiviral therapy, breastfeeding is not recommended. ( J CLIN EXP HEPATOL 2012;2:366-381) A pproximately 400 million people are chronically infected with hepatitis B virus (HBV) worldwide, 1 and almost half have acquired their infections either through mother to infant transmission or in early childhood, especially in countries where HBV has intermediate to high prevalence.2 In Asia, 8%-10% of the population is chronically infected with HBV, and up to 50% of new cases of hepatitis B infection are due to mother to infant transmission.3 In contrast, the majority of new hepatitis B cases in developed countries are the result of horizontal transmission in adulthood. Before the adoption of standard passive-active immunoprophylaxis treatment, approximately 70%-90% of infants born to hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers became chronically infected with HBV. 4 The mother to infant transmission rate was reduced to 5%-10% when infants received appropriate postnatal hepatitis B immunoglobulin (HBIg) and a series of HBV vaccines. However, despite passive-active immunoprophylaxis provided to infants, up to 8%-30% of infants born to highly viremic mothers still become infected with HBV (Figures 1-3). This review will address several issues important to chronic hepatitis B virus infection and pregnancy including effect of pregnancy on chronic HBV infection, effect of chronic HBV infection on pregnancy, mother to infant transmission, safety data on HBV antivirals during pregnancy, management of chronic HBV infection in women who desire pregnancy or become pregnant while taking antivirals. PREVALENCE OF CHRONIC HEPATITIS B VIRUS INFECTION AMONG PREGNANT WOMEN IN INDIAThe prevalence of chronic HBV infection varies widely, with rates ranging from 0.1% to 20% in different parts of the world.2 "High" prevalence (HBsAg positivity rates > 8%) regions include the Asia (except Japan), parts of the Middle East, sub-Saharan Africa, and the Amazon basin. "Intermediate" (2%-7% HBsAg positive) prevalence regions include, the Indian subcontinent, parts of central Asia and the Middle East, Eastern and Southern Europe, as well as parts of South America. "Low" prevalence (<2% HBsAg positive) regions include the United States, Northern Europe, Australia, Japan and the southern part of South America. Overall, 45% of the world population lives in "high" prevalence regions.The HBsAg positivity rate of Hepatitis B in India is different in the different regions of the country. The overall chronic HBsAg positivity rate is often quoted as being 4.7%.5 In India, the prevalence rate of HBsAg...

show abstract

“…Most in vitro studies have used concentrated, whole virions or human serum samples as virus sources and primary human hepatocytes or human liver cell lines, e.g., HepG2, HuH7, and PH5CH8, as target cells (12,13,21,31,41). However, their infectivities are not so high, and human serum samples and human hepatocytes are not readily available.…”

Section: Hepatitis B Virus (Hbv) Which Belongs To the Virus Genusmentioning

confidence: 99%

Formation of Vesicular Stomatitis Virus Pseudotypes Bearing Surface Proteins of Hepatitis B Virus

Saha

Tanaka

Jinno-Oue

et al. 2005

J Virol

View full text Add to dashboard Cite

Hepatitis B virus (HBV), which belongs to the virus genusHepadnaviridae, is an important etiological agent for acute and chronic hepatitis as well as liver cirrhosis or primary hepatocellular carcinoma (15, 18). The surface proteins of HBV contain three related HBV-encoded glycoprotein species, termed large (L), middle (M), and small (S) proteins (37). As shown in Fig. 1A, all surface proteins are produced from a single open reading frame (ORF) by the use of three different translational start sites that divide this ORF into three domains: preS1, preS2, and S. Translation from the first ATG yields L protein, comprising 390 amino acids (aa), whereas translation from the ATG at aa positions 109 and 164 generates M and S proteins, respectively. The three proteins are posttranslationally modified: each of them exhibits a glycosylation site in the S domain, and an additional glycosylation occurs in the preS2 region of the M protein (Fig. 1A). Either M or S protein, when expressed alone, can be secreted as virus-like particles (25, 45). In contrast, L protein cannot be secreted when expressed alone; instead, it is mainly retained within the endoplasmic reticulum and pre-Golgi regions in the form of intraluminal particles (27,45). It has been reported that the sequence between amino acids 3 and 77 of the preS1 region is necessary for infection of primary human hepatocytes in vitro (21). The preS2 region of M protein has been thought to be involved in polymerized albumin-mediated interaction of HBV (48), but no precise function has yet been definitively assigned to the preS2 region of the M protein. Kann et al. (18) proposed that in association with the preS1 domain of L protein, the preS2 domain of M protein might have a supportive function in viral attachment. Thus, it is still necessary to study the roles of all three proteins in the HBV infection process to clarify the process of entry of HBV into cells.Analysis of HBV infection in vitro has still been difficult due to the lack of a suitable culture system, i.e., lack of susceptible cell lines or of cells producing HBV abundantly. Most in vitro studies have used concentrated, whole virions or human serum samples as virus sources and primary human hepatocytes or human liver cell lines, e.g., HepG2, HuH7, and PH5CH8, as target cells (12,13,21,31,41). However, their infectivities are not so high, and human serum samples and human hepatocytes are not readily available. Despite these difficulties, infection of cells with viral inocula or transfection of cells with HBV DNA has been employed in order to analyze HBV infection in vitro (12,14,46). In vitro infection of human hepatoma (HepG2) cells with hepatitis B virus obtained from the serum of a chronic HBV patient was first reported by Bchini et al. (3).There seems to be only one report that describes an HBV pseudotype: murine leukemia virus (MLV) pseudotype, expected to bear the L and S proteins of HBV (41). The reported MLV(HBV) pseudotype, which was prepared after cotransfection of 293T cells with plasmids expressing...

show abstract

Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes

Cited by 100 publications

References 41 publications

Hepatoprotective Effects of Whey Protein onD-Galactosamine-Induced Hepatitis and Liver Fibrosis in Rats

Hepatoprotective Effects of Whey Protein onD-Galactosamine-Induced Hepatitis and Liver Fibrosis in Rats

Chronic Hepatitis B Virus Infection and Pregnancy

Formation of Vesicular Stomatitis Virus Pseudotypes Bearing Surface Proteins of Hepatitis B Virus

Contact Info

Product

Resources

About